CorVista System with PH Add-On vs Rapid RV/LV

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CorVista System with PH Add-On

by CorVista Health

Rapid RV/LV

by RapidAI (formerly iSchemaView)

AI Verdict

These tools are adjacent as both are FDA-cleared AI platforms for cardiovascular and pulmonary assessment. However, Tool A offers non-invasive diagnosis for coronary artery disease and pulmonary hypertension using physiological signals, while Tool B specifically analyzes CTPA scans for pulmonary embolism severity.

Choose CorVista System with PH Add-On if…

Choose CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for initial assessment of coronary artery disease and pulmonary hypertension. This tool is ideal for settings where avoiding radiation, contrast agents, injections, fasting, or exercise is paramount, providing quick results within minutes without the need for specialized imaging equipment. It's well-suited for early screening or follow-up in outpatient clinics or primary care.

View CorVista System with PH Add-On →

Choose Rapid RV/LV if…

Choose Rapid RV/LV if your primary need is the immediate, AI-powered assessment of pulmonary embolism severity directly from CTPA scans. This tool is best suited for emergency departments or critical care units where rapid, objective quantification of right ventricular strain (via RV/LV ratio) is critical for guiding treatment decisions and patient triage following a confirmed or suspected PE. It integrates seamlessly into existing CTPA workflows to provide automated measurements and reduce inter-rater variability.

View Rapid RV/LV →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CorVista System with PH Add-On	Rapid RV/LV
Pricing	Unknown	Contact vendor for pricing information.
Deployment	Cloud-based, point-of-care system.	On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CorVista System with PH Add-On

Tool A, the CorVista System, offers superior usability due to its entirely non-invasive, point-of-care nature, requiring no radiation, contrast agents, injections, fasting, or exercise. This significantly reduces patient burden and streamlines clinical workflow compared to imaging-based diagnostics.

Clinical Value

CorVista System with PH Add-On

Both tools are FDA-cleared and address critical cardiovascular conditions. However, Tool A provides rapid, non-invasive assessment for two conditions (coronary artery disease and pulmonary hypertension) at the point of care, potentially enabling broader screening and earlier detection without the need for more invasive or resource-intensive procedures.

Pricing & Value

Tie

Both Tool A and Tool B require direct contact with the vendor for pricing information. Without transparent pricing details or specific cost-effectiveness studies for either product, it is impossible to determine which offers better value.

Enterprise Readiness

Rapid RV/LV

Tool B explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), alongside flexible deployment options including on-premises or hybrid solutions. This offers greater assurance and adaptability for integration into diverse enterprise IT infrastructures and security frameworks compared to Tool A's 'likely' compliance and cloud-only deployment.

Innovation

CorVista System with PH Add-On

Tool A demonstrates higher innovation by pioneering a completely non-invasive, point-of-care AI diagnostic platform that bypasses traditional, more burdensome diagnostic methods for cardiovascular diseases. This represents a significant paradigm shift in diagnostic approach.

Support & Docs

Tie

The provided structured facts do not contain any information regarding the availability, quality, or scope of support and documentation for either Tool A or Tool B. Therefore, a head-to-head comparison on this dimension is not possible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CorVista System with PH Add-On	Rapid RV/LV
Name	CorVista System with PH Add-On	Rapid RV/LV
Primary Use Case / Disease Assessed	Rapid assessment of coronary artery disease and pulmonary hypertension	Rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans
Company	Analytics for Life	RapidAI (formerly iSchemaView)
Input Data / Modality	Non-invasive, point-of-care (analyzes cardiac and hemodynamic signals; no radiation, contrast agents, injections, fasting, or exercise required)	CTPA scans
Key Analysis / Output	Machine-learned algorithms for analysis of CAD and PH; Rapid results within minutes via secure web portal.	Automated measurement of RV/LV ratio from CTPA images; Annotated images; Rapid results within minutes.

Videos

Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and Rapid RV/LV.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiovascular conditions do these tools help diagnose or assess?

Tool A, the CorVista System with PH Add-On, is an FDA-cleared AI diagnostic platform for the rapid, non-invasive assessment of coronary artery disease (CAD) and pulmonary hypertension (PH) using machine-learned algorithms. Tool B, Rapid RV/LV, is an FDA-cleared AI tool specifically for the rapid assessment of pulmonary embolism (PE) severity by automatically measuring right and left ventricle ratios from CTPA scans.

What type of patient data or imaging is required for each tool's analysis?

The CorVista System with PH Add-On analyzes cardiac and hemodynamic signals non-invasively, requiring no radiation, contrast agents, injections, fasting, or exercise. In contrast, Rapid RV/LV performs AI-powered analysis directly on CTPA images to automatically measure right and left ventricle diameters and calculate the RV/LV ratio.

What is the patient experience and preparation involved with using each diagnostic tool?

The CorVista System with PH Add-On is a non-invasive, point-of-care solution that requires no radiation, contrast agents, injections, fasting, or exercise. Rapid RV/LV, however, requires a prior CTPA scan, as its analysis is based on these imaging results, and provides rapid results within minutes of the scan.

What specific diagnostic insights or measurements do these tools provide to aid clinical decision-making?

The CorVista System with PH Add-On provides a binary output indicating the likelihood of elevated mean pulmonary arterial pressure (mPAP), an indicator of pulmonary hypertension, and assesses for coronary artery disease. Rapid RV/LV automatically calculates the RV/LV ratio from CTPA images and provides annotated images showing ventricular measurements to assess pulmonary embolism severity.

Which medical specialties are primarily supported by each of these AI diagnostic platforms?

The CorVista System with PH Add-On is designed for use in Cardiology, Internal Medicine, and Pulmonology. Rapid RV/LV is relevant for Cardiology, Pulmonology, and Radiology, given its AI-powered analysis of CTPA images.